abstract |
The present invention relates to a CCR5 antagonist compound for elevating high density lipoprotein (HDL) particles in a patient, improving plasma lipid profile in a patient or reducing triglycerides in a patient. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, an HMG-CoA reductase inhibitor compound and a pharmaceutically acceptable carrier. The invention also relates to a pharmaceutical composition comprising a CCR5 antagonist compound, a cholesteryl ester transfer protein (CETP) inhibitor compound and a pharmaceutically acceptable carrier. |